Peptide supply chain (revision 12)
Old revision·17:13, 20 Jan 2025·Chromatokid
| Peptide supply chainProcess overview | |
|---|---|
Synthesis, purification and finishing are usually co-located; freight, warehousing and repackaging usually are not. Most documentary gaps open at a handover. | |
| Stages | |
| Upstream | Solid-phase synthesis; cleavage |
| Midstream | Preparative purification; counterion exchange |
| Downstream | Lyophilisation; fill and finish; labelling |
| Distribution | Freight; regional warehousing; dispatch |
| Topic infobox · conventions | |
A research peptide passes through at least six operations between a resin bead and a purchaser's hand: solid-phase synthesis, cleavage from the resin, preparative purification, lyophilisation, filling and closure, and freight — frequently followed by a period in a regional warehouse and, in some arrangements, by repackaging.[1]
Each operation has a characteristic failure mode, and the great majority of quality observations made downstream are attributable to one of them rather than to a general property of the material or the seller.[2] Knowing which stage produces which observation is what allows a purchaser to read a certificate as evidence about something rather than as a number.
The documentary shape of the chain matters as much as the physical one. A certificate is created once, at release, at the end of finishing. Everything that happens afterwards — freight, storage, the interval in a warehouse, any repackaging — happens after the document exists and is not described by it. Most of the gaps this wiki records at supplier level are gaps of that kind.[3]
The stages and what each can go wrong at
[edit]| Stage | What happens | Characteristic failure mode | Visible in |
|---|---|---|---|
| Synthesis | Residues coupled one at a time on a solid support | Deletion sequences from incomplete coupling | Related-substance peaks close to the main peak |
| Cleavage | Peptide released from resin, side chains deprotected | Incomplete deprotection; scavenger adducts | Mass spectrometry; not always in ultraviolet |
| Purification | Preparative reverse-phase chromatography | Collection window too wide; co-eluting species carried through | Area percent purity on a shallower analytical gradient |
| Counterion exchange | Trifluoroacetate exchanged, or not | Counterion left in place and unreported | Peptide content; ion chromatography |
| Lyophilisation | Frozen solution dried under vacuum | Collapse; high residual moisture | Cake appearance; Karl Fischer titration |
| Fill and finish | Solution or powder into vials, stoppered, crimped | Fill variation; closure integrity | Weight check; appearance on reconstitution |
| Freight and storage | Transport, customs, warehousing | Temperature excursion; undocumented storage interval | Nothing on the certificate |
The final row is the one with no entry in the last column, and that is the point of the table. Everything above it leaves a trace in a determination somebody performs. Freight and storage leave a trace only if a data logger travelled with the consignment, and one usually does not.[3]
References
- ^ United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
- ^ World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. Sets out the stage-by-stage controls that unregulated supply is not obliged to operate.
- ^ a b Purchaser-submitted reports and accompanying documentation held by PeptidePedia, 2024–2026, including descriptions of dispatch origin and packaging. A self-selected sample.